36 studies on SS-31 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 2,019 published SS-31 COA source records from third-party laboratories, covering 725 publicly attributable vendor identities. Across 1,841 records with positive numeric purity, the arithmetic mean is 99.78%. 3 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 83 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-16. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 10 mg | $11.17 | $10.50–$12.00 | $1.12 | 3 sources · 3 offers |
| 30 mg | $29.00 | $29.00–$29.00 | $0.97 | 1 source · 1 offer |
| 50 mg | $39.50 | $35.50–$45.50 | $0.79 | 3 sources · 3 offers |
| 100 mg | $71.50 | $71.50–$71.50 | $0.71 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-16. Aggregate calculated: 2026-10-18T04:26:51.147732+00:00. Calculation time is not a laboratory observation date.
Within that total, 652 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 48 | 99.77% | 0 of 36 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified | Reveal with Pro → | |
| #2 | 34 | 99.76% | 0 of 34 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 13 | 99.79% | 0 of 13 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120334 (99.87%) · #120184 (99.7%) · #119956 (99.84%) · #120284 (99.81%) · #120238 (99.04%) · #120220 (99.92%)
**Promoting elaboration as a core learning strategy could significantly enhance medical student satisfaction with their curriculum.** This finding suggests that educators should prioritize teaching methods that encour…
This review provides a crucial roadmap for understanding and addressing **diabetic silent myocardial ischemia (DSMI)**. **Clinicians can now consider a broader range of diagnostic markers and therapeutic strategies be…
This study highlights **Elamipretide's potential to directly address skeletal muscle weakness and exercise intolerance in HFpEF**, a critical unmet need for patients. By targeting mitochondrial dysfunction and stabili…
This review synthesizes how multi-omics approaches are revealing critical mitochondrial-endothelial crosstalk mechanisms underlying cardiometabolic diseases and their vascular complications.
This review highlights a pivotal shift in leveraging Traditional Chinese Medicine (TCM) for neurological conditions, moving beyond its traditional limitations. **For biohackers and clinicians, this means the therapeut…
This review fundamentally shifts our understanding of **gestational diabetes mellitus** (GDM) by emphasizing the critical, active roles of **mitochondrial dysfunction** and **redox imbalance**, moving beyond a sole fo…
**SS-31 shows promise as a therapeutic strategy for Parkinson's disease by directly targeting α-synuclein pathology and mitochondrial health.** For peptide users and biohackers, these findings highlight SS-31's potent…
Understanding the role of **extracellular vesicles (EVs)** in **cardiac surgery-associated acute kidney injury (CSA-AKI)** shifts the focus from purely hemodynamic factors to novel cellular and molecular mechanisms. *…
Understanding the specific mechanisms by which **HIV-1 gp120 drives neurocognitive decline** is crucial for developing targeted therapies beyond cART. This review underscores that simply suppressing viral load isn't e…
Understanding the intricate mechanisms of **CIRI** and **BBB dysfunction** is crucial for developing novel therapeutic strategies in stroke. This review provides a comprehensive overview that could guide future resear…
This review fundamentally shifts the understanding of **Dry Eye Disease** (DED) from a purely symptomatic condition to one driven by identifiable molecular mechanisms, particularly **oxidative stress** and **mitochond…
This research is significant because it identifies Quercetin, a natural flavonoid, as a potential therapeutic agent for renal ischemia-reperfusion injury, a condition with limited current treatment options. The findin…
This review is crucial because it highlights the urgent need for effective treatments for dry AMD, a condition affecting millions globally with no current cure. The identification of innovative technologies like gene …
This comprehensive review underscores the critical role of mitochondria as a promising therapeutic target for preventing and treating acute kidney injury (AKI) caused by ischemia-reperfusion injury (IRI). By elucidati…
SS-31 represents a highly promising therapeutic strategy for a wide range of conditions characterized by mitochondrial dysfunction, offering a direct and targeted approach to cellular protection. Its unique ability to…
This review provides novel insights into the critical role of mitochondrial calcium dysregulation in heart failure, underscoring its potential as a therapeutic target. The discussion of mCa2+ uniporter (MCU) inhibitor…
These findings underscore SS-31's significant potential as a novel therapeutic agent for managing and treating inflammatory liver conditions. By elucidating its mechanism through ATG5-dependent autophagy, this researc…
This review underscores the pivotal role of mitochondria in determining the trajectory of recovery and long-term neurological health after TBI. By identifying mitochondrial dysfunction as a key pathological mechanism,…
This research fundamentally shifts our understanding of how telomere length is established and inherited, demonstrating its modifiability during the earliest stages of embryonic development. The ability to intervene w…
This research provides compelling evidence that mitochondrial dysfunction is a primary driver of age-related aortic degeneration. The successful intervention with elamipretide highlights its potential as a therapeutic…
This research provides strong evidence that mitochondrial dysfunction is a primary driver of aortic aging, offering a novel understanding of age-related cardiovascular decline. The successful restoration of mitochondr…
Friedreich Ataxia (FRDA) currently lacks effective treatments for vision loss, a symptom that significantly impacts patients' independence and quality of life. Positive results from this pilot study could validate Ela…
Free, no account — handy when you're working with SS-31.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account